Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Privately-owned Grünenthal estimates the Nebido brand will add about €100…
Privately-owned Grünenthal estimates the Nebido brand will add about €100 million to its EBITDA in 2023.